After Teva Pharmaceutical snagged the OK to launch its Victoza generic in 2023, another copycat has secured a launch timeline for its generic to Novo Nordisk’s aging GLP-1 mainstay.

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...

Novo Nordisk has at least four more years to build up its newer diabetes drugs before they'll have to compete with Teva's knockoff versions of its own blockbuster Victoza.

Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades. The FDA says the okay ...

Novo Nordisk launched a consumer campaign for Victoza, emphasizing the product’s ability to bring down blood sugar levels and body weight in patients with type 2 diabetes. The campaign features print ...

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...

Novo Nordisk has not disclosed its pricing plans for Saxenda yet, although there are rumours it is considering a price of $9,000 per year, which would be a significant premium to Victoza.

Summary. Results from Novo Nordisk's cardiovascular outcomes study with their diabetes drug Victoza were just released. A very positive 15% reduction in primary composite outcome and 22% reduction ...

Novo Nordisk expects to launch Victoza® in Japan in the first half of 2010 upon completion of price negotiations. About Victoza® Once-daily Victoza® is the first human Glucagon-Like Peptide-1 ...